Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study)

Dens, Joseph; Desmet, Walter; Coussement, Patrick; Scheerder, Ivan K. De; Kostopoulos, Konstantinos; Kerdsinchai, Pitsanu; Supanantaroek, Chumpol; Piessens, Jan

doi:10.1016/s0002-9149(00)01267-4

Cited by 53 publications

(62 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rosuvastatin and pravastatin are known to have very low lipophilicity than other statins (in descending order: simvastatin > fluvastatin > atorvastatin > rosuvastatin > pravastatin) 24. Statin lipophilicity does not correlate with the relative risk of statin‐induced MAEs nor the MAE onset timing for any statin.…”

Section: Discussionmentioning

confidence: 99%

“…The magnitude of HMG‐CoA reductase 50% inhibitory concentration (IC 50 ) for each statin was in the order of rosuvastatin < atorvastatin < simvastatin < fluvastatin < pravastatin 24. Atorvastatin or rosuvastatin, which possesses a high HMG‐CoA reductase inhibitory activity, is considered high‐intensity statin therapy that reduces LDL cholesterol by more than 50%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Onset timing of statin‐induced musculoskeletal adverse events and concomitant drug‐associated shift in onset timing of MAEs

Akimoto

Negishi

Oshima

et al. 2018

Pharmacology Res & Perspec

View full text Add to dashboard Cite

To evaluate the onset timing of musculoskeletal adverse events (MAEs) that develop during statin monotherapy and to determine whether concomitant drugs used concurrently with statin therapy shifts the onset timing of MAEs. Cases in which statins (atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and pravastatin) were prescribed were extracted from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Data Files. The onset timing of MAEs during statin monotherapy was evaluated by determining the difference between statin start date and MAE onset date. The use of concomitant drugs with statin therapy was included in the analysis. Statins used in combination with concomitant drugs were compared with statin monotherapy to determine if the use of concomitant drugs shifted the onset timing of MAEs. The onset of MAEs was significantly faster with atorvastatin and rosuvastatin than with simvastatin. A difference in onset timing was not detected with other statins because the number of cases was too small for analysis. When evaluating concomitant drug use, the concomitant drugs that shifted the onset timing of MAEs could not be detected. Statins with strong low‐density lipoprotein cholesterol‐lowering effects (atorvastatin and rosuvastatin) contributed not only to a high risk of MAE onset, but also to a shorter time‐to‐onset. No concomitant drug significantly shifted the onset timing of MAEs when used concurrently with statins.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Onset timing of statin‐induced musculoskeletal adverse events and concomitant drug‐associated shift in onset timing of MAEs

Akimoto

Negishi

Oshima

et al. 2018

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…In 5 trials with 12,342 randomized patients (Table 2), the experimental agent was a dihydropyridine calcium-channel blocker: amlodipine in CAMELOT/Aml (41), PREVENT (42,43), and IDNT2 (33−35); nifedipine GITS (gastro-intestinal therapeutic system) in ACTION (44,45); and nisoldipine in NICOLE (46,47). In 9 trials with 43,227 randomized patients ( (57); and trandolapril in PEACE (58).…”

Section: Placebo-controlled Secondary Prevention Trialsmentioning

confidence: 99%

“…All patients randomized in these trials were high risk patients with a history of cardiovascular disease and/ or diabetes mellitus (54−56), nephropathy (33,35), documented coronary heart disease (41, 43, 44, 46−49, 57, 58) or a previous cerebrovascular accident (51,59). All (33,41,44,49,54,55,58) but 5 (43,46,48,51,57) of the placebo-controlled secondary prevention trials had a composite primary endpoint (Tables 2 and 3). In 3 trials (41), the composite endpoint included coronary (41,58) or peripheral (44) revascularization procedures.…”

Section: Placebo-controlled Secondary Prevention Trialsmentioning

confidence: 99%

“…point consisted only of the rate of change of carotid (43,48) or coronary (46,57) atherosclerosis, and hard endpoints, such as stroke or myocardial infarction, were only secondary outcomes. The use of composite endpoints with varying definitions (Tables 2 and 3) and the wide range of secondary endpoints made obtaining pooled estimates for overall treatment effects difficult.…”

Section: Placebo-controlled Secondary Prevention Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials

et al. 2005

View full text Add to dashboard Cite

show abstract

Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus

Turnbull

Neal²,

Algert³

et al. 2005

Arch Intern Med

693

View full text Add to dashboard Cite

show abstract

Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study)

Cited by 53 publications

References 22 publications

Onset timing of statin‐induced musculoskeletal adverse events and concomitant drug‐associated shift in onset timing of MAEs

Onset timing of statin‐induced musculoskeletal adverse events and concomitant drug‐associated shift in onset timing of MAEs

Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials

Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus

Contact Info

Product

Resources

About